Not yet recruitingPhase 1NCT07177079

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kittika Poonsombudlert
Principal Investigator
Kittika Poonsombudlert, MD
University of Iowa
Intervention
Azacitidine(drug)
Enrollment
30 enrolled
Eligibility
18-75 years · All sexes
Timeline
20262029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07177079 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials